Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

BACKGROUND: Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal cancer (mCRC). Here, the oral tyrosine kinase Src inhibitor, dasatinib, was investigated in combination with FOLFOX and cetuximab....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Parseghian, Christine M., Parikh, Nila U., Wu, Ji Yuan, Jiang, Zhi-Qin, Henderson, Laura, Tian, Feng, Pastor, Brice, Ychou, Marc, Raghav, Kanwal, Dasari, Arvind, Fogelman, David R., Katsiampoura, Anastasia D., Menter, David G., Wolff, Robert A., Eng, Cathy, Overman, Michael J., Thierry, Alain R., Gallick, Gary E., Kopetz, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540760/
https://ncbi.nlm.nih.gov/pubmed/28280091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3138
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados